Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Human Milk and Lactation

  • Author: Carol L Wagner, MD; Chief Editor: Ted Rosenkrantz, MD  more...
 
Updated: Feb 02, 2015
 

Background

Breast milk is thought to be the best form of nutrition for neonates and infants. The properties of human milk facilitate the transition of life from in utero to ex utero. This dynamic fluid provides a diverse array of bioactive substances to the developing infant during critical periods of brain, immune, and gut development. The clinician must be familiar with how the mammary gland produces human milk and how its properties nourish and protect the breastfeeding infant.

Clinicians play a crucial role in a mother's decision to breastfeed and can facilitate her success in lactation. Although a mother may not be aware of the evidence indicating that breast milk contributes to her baby's short-term and long-term well-being, she has developed certain attitudes and cultural beliefs about breastfeeding. The issue of bonding between mother and newborn may be a strong factor; however, stronger cultural or societal barriers may result in the decision to formula feed. Such issues must be understood for successful counseling. The mother makes her decision regarding breastfeeding prior to delivery in more than 90% of cases; therefore, her choice of infant nutrition should be discussed starting in the second trimester and continue as part of an ongoing dialogue during each obstetric visit.

This article reviews the development of the mammary gland (mammogenesis), the process through which the mammary gland develops the capacity to secrete milk (lactogenesis), the process of milk production (lactation), and the specific properties of human milk that make it unique and appropriate for human infants. In a related article titled Counseling the Breastfeeding Mother, the mechanics of breastfeeding and evaluation of the breastfeeding mother-infant dyad are discussed. Such articles are intended to be overviews. For a more in-depth treatise, please refer to textbooks by Lawrence and Lawrence (2005)[1] and the American Academy of Pediatrics (2006).[2] Guidelines for breastfeeding and the use of human milk have been established by the American Academy of Pediatrics.[3]

Next

Pathophysiology

Mammogenesis

The breast begins to develop in utero, undergoing the first of many developmental changes necessary for proper breastfeeding to occur. A bulb-shaped mammary bud can be discerned in the fetus at 18-19 weeks' gestation. Inside the bud, a rudimentary mammary ductal system is formed, which is present at birth. After birth, growth of the gland parallels that of the child until puberty. The normal anatomy of the mammary gland following pubertal development is shown in the images below.[4]

Schematic diagram of the breast. Schematic diagram of the breast.
Frontal view of lactating breast. Frontal view of lactating breast.

The basic unit of the mammary gland is the alveolus or acinus cell that connects to a ductule. Each ductule was believed to independently drain to a duct that, in turn, emptied into lactiferous sinuses. These lactiferous sinuses drain to 15-25 openings in the nipple, allowing milk to flow to the recipient infant.

More recently, researchers such as Ramsay et al (2005) have questioned the existence of lactiferous sinuses.[5] Extensive real-time ultrasonography of 21 fully lactating women provided better understanding of the anatomy of the lactating human breast, as shown below.

(A) Ultrasound image of milk duct in the lactating (A) Ultrasound image of milk duct in the lactating breast. The duct appears as a branching hypoechoic structure within echogenic glandular tissue. (B) The ducts focused on the nipple (N) to the periphery of the breast. The walls are echogenic (up arrow) and the lumen hypoechoic (asterisk). The first branch of this duct (-->) is imaged almost directly under the nipple.

On ultrasonography, milk ducts appear as superficial, hypoechoic tubular structures with echogenic walls whose milk-fat globules appear as echoes. The ducts are easily compressed, do not display typical sinuses, and anatomically appear to transport the milk rather than store it.

The ducts can be traced from the base of the nipple back into the parenchyma. The mean number of main ducts greater than 0.55 mm diameter at the base of the nipple was approximately 10 for the left breast and 9 for the right breast. Although the duct diameter was increased at multiple branch points, the typical saclike appearance of lactiferous sinuses under the areola was not observed during scanning. The mean number of ducts and the diameter of the main ducts were not related to nipple diameter, areola radius, or milk production for individual breasts. Adipose and glandular tissue distribution differed widely among women but not between breasts. In addition, the proportion of glandular and fat tissue and the number and size of ducts were not related to milk production.

At puberty, released estrogen stimulates breast tissue to enlarge through growth of mammary ducts into the preexisting mammary fat pad. Progesterone, secreted in the second half of the menstrual cycle, causes limited lobuloalveolar development. The effects of estrogen and progesterone facilitate the formation of the characteristic structure of the adult breast, which is the terminal duct lobular unit. However, full alveolar development and maturation of epithelium requires the hormones of pregnancy.

Lactogenesis

In lactogenesis, the mammary gland develops the capacity to secrete milk. Lactogenesis includes all processes necessary to transform the mammary gland from its undifferentiated state in early pregnancy to its fully differentiated state sometime after pregnancy. This fully differentiated state allows full lactation. The 2 stages of lactogenesis are discussed below.

Stage 1 occurs by mid pregnancy. In stage 1, the mammary gland becomes competent to secrete milk. Lactose, total protein, and immunoglobulin concentrations increase within the secreted glandular fluid, whereas sodium and chloride concentrations decrease. The gland is now sufficiently differentiated to secrete milk, as evidenced by the fact that women often describe drops of colostrum on their nipples in the second or third trimester. However, high circulating levels of progesterone and estrogen hold the secretion of milk in check.

Stage 2 of lactogenesis occurs around the time of delivery. It is defined as the onset of copious milk secretion. In stage 2, blood flow, oxygen, and glucose uptake increase, and citrate concentration increases sharply. Increased milk citrate is considered a reliable marker for the second stage of lactogenesis. Progesterone plays a key role in this stage. Removal of the placenta (ie, the source of progesterone during pregnancy) is necessary for the initiation of milk secretion; however, the placenta does not inhibit established lactation. Work by Haslam and Shyamala reveals that progesterone receptors are lost in lactating mammary tissues, thus decreasing the inhibitory effect of circulating progesterone.[6, 7] In addition, maternal secretion of insulin, growth hormone (GH), cortisol, and parathyroid hormone (PTH) facilitates the mobilization of nutrients and minerals that are required for lactation.

The stages of lactation can be summarized as follows (adapted from Riordan and Auerbach, 1998):[8]

  • Mammogenesis: Mammary (breast) growth occurs. The size and weight of the breast increase.
  • Lactogenesis
    • Stage 1 (late pregnancy): Alveolar cells are differentiated from secretory cells.
    • Stage 2 (day 2 or 3 to day 8 after birth): The tight junction in the alveolar cell closes. Copious milk secretion begins. Breasts are full and warm. Endocrine control switches to autocrine (supply-demand) control.
  • Galactopoiesis (later than 9 d after birth to beginning of involution): Established secretion is maintained. Autocrine system control continues.
  • Involution (average 40 d after last breastfeeding): Regular supplementation is added. Milk secretion decreases from the buildup of inhibiting peptides.

Lactation

See the list below:

  • Two essential hormones (prolactin and oxytocin)
    • During the second stage of lactogenesis, the breast becomes capable of milk production. For the ongoing synthesis and secretion of human milk, the mammary gland must receive hormonal signals. These signals, which are in direct response to stimulation of the nipple and areola (mammae), are then relayed to the central nervous system. This cyclical process of milk synthesis and secretion is termed lactation. Lactation occurs with the help of 2 hormones, prolactin (PRL) and oxytocin. Although PRL and oxytocin act independently on different cellular receptors, their combined actions are essential for successful lactation.
  • Prolactin
    • Milk synthesis occurs in the mammary gland epithelial cells in response to PRL activation of epithelial cell PRL receptors. PRL, a polypeptide hormone synthesized by lactotrophic cells in the anterior pituitary, is structurally similar to GH and placental lactogen (PL), which appear to have cytokine functions. The secretion of PRL appears to be both positively and negatively regulated; however, its main locus of control comes from hypothalamic inhibitory factors, the most important of which is dopamine, acting through the D2 subclass of dopamine receptors present in lactotrophs. PRL stimulates mammary glandular ductal growth and epithelial cell proliferation and induces milk protein synthesis.
    • Research during the past several decades has led to a deeper understanding of PRL's role in the body. PRL-related knockout models support PRL's pivotal role in lactation and reproduction, which suggests that most of PRL's target tissues are modulated rather than dependent on PRL.
    • The significance of PRL can be seen in the inhibition of lactogenesis using bromocriptine and other dopamine analogues, which are PRL inhibitors.
  • Oxytocin
    • The other important hormone involved in the milk ejection or letdown reflex is oxytocin. When the neonate is placed at the breast and begins suckling, oxytocin is released. The suckling infant stimulates the touch receptors that are densely located around the nipple and areola. The tactile sensations create impulses that, in turn, activate the dorsal root ganglia via the intercostals nerves (4, 5, 6). These impulses ascend the spinal cord, creating an afferent neuronal pathway to both the paraventricular nuclei of the hypothalamus where oxytocin is synthesized and secreted by the pituitary gland. The stimulation of the nuclei causes the release of oxytocin down the pituitary stalk and into the posterior pituitary gland, where oxytocin is stored.
    • The infant's suckling creates afferent impulses that stimulate the posterior pituitary gland. This releases oxytocin in a pulsatile fashion to adjacent capillaries, traveling to the mammary myoepithelial cell receptors that, in turn, stimulate the cells to contract. Oxytocin causes the contraction of the myoepithelial cells that line the ducts of the breast. These smooth muscle–like cells, when stimulated, expel milk from alveoli into ducts and subareolar sinuses that empty through a nipple pore.
  • Milk secretion directly correlates with synthesis
    • The regulation of milk synthesis is quite efficient. Milk synthesis remains remarkably constant at approximately 800 mL/d. However, the actual volume of milk secreted may be adjusted to the requirement of the infant by feedback inhibitor of lactation, a local factor secreted into the milk; therefore, the rate of milk synthesis is related to the degree of breast emptiness or fullness. The emptier breast produces milk faster than the fuller one.
    • Milk production is responsive to maternal states of well-being. Thus, stress and fatigue adversely affect a woman's milk supply. The mechanism for this effect is the down-regulation of milk synthesis with increased levels of dopamine, norepinephrine, or both, which inhibit PRL synthesis. Relaxation is key for successful lactation.

Biochemistry of human milk

Human milk is a unique, species-specific, complex nutritive fluid with immunologic and growth-promoting properties. This unique fluid actually evolves to meet the changing needs of the baby during growth and maturation. Milk synthesis and secretion by the mammary gland involve numerous cellular pathways and processes (summarized in the table below).

The pathways for milk secretion and synthesis by t The pathways for milk secretion and synthesis by the mammary epithelial cell. I: Exocytosis of milk protein, lactose, and other components of the aqueous phase in Golgi-derived secretory vesicles. II: Milk fat secretion via the milk fat globule. III: Direct movement of monovalent ions, water, and glucose across the apical membrane of the cell. IV: Transcytosis of components of the interstitial space. V: The paracellular pathway for plasma components and leukocytes. Pathway V is open only during pregnancy, involution, and in inflammatory states such as mastitis. SV = Secretory vesicle; RER = Rough endoplasmic reticulum; BM = Basement membrane; MFG = Milk fat globule; CLD = Cytoplasmic lipid droplet; N = Nucleus; PC = Plasma cell; FDA = Fat-depleted adipocyte; TJ = Tight junction; GJ = Gap junction; D = Desmosome; ME = Myoepithelial cell.

The processing and packaging of nutrients within human milk changes over time as the recipient infant matures. For example, early milk or colostrum has lower concentrations of fat than mature milk but higher concentrations of protein and minerals (see the image below). This relationship reverses as the infant matures.

Lactose, protein, and total lipid concentrations i Lactose, protein, and total lipid concentrations in human milk.

Important biochemical points are discussed below.

Fore and hind milk (important differences)

In addition to the changes from colostrum to mature milk that mirror the needs of the developing neonate, variation exists within a given breastfeeding session. The milk first ingested by the infant (fore milk) has a lower fat content. As the infant continues to breastfeed over the next several minutes, the fat content increases. This hind milk is thought to facilitate satiety in the infant. Finally, the diurnal variations in breast milk reflect maternal diet and daily hormonal fluctuations.

Specific enzymes to aid neonatal digestion

Human milk contains various enzymes; some are specific for the biosynthesis of milk in the mammary gland (eg, lactose synthetase, fatty acid synthetase, thioesterase), whereas others are specific for the digestion of proteins, fats, and carbohydrates that facilitate the infant's ability to break down food and to absorb human milk. Certain enzymes also serve as transport moieties for other substances, such as zinc, selenium, and magnesium.

Three-dimensional structure of human milk

Under a microscope, the appearance of human milk is truly amazing. Although it is a fluid, human milk has substantial structure in the form of compartmentation. Nutrients and bioactive substances are sequestered within the various compartments of human milk. The most elegant example of this structure involves lipids. Lipids are enveloped at the time of secretion from the apical mammary epithelial cell within its plasma membrane, becoming the milk-fat globule. Certain proteins, growth factors, and vitamins also become sequestered within this milk-fat globule and are embedded within the membrane itself.

The membrane acts as a stabilizing interface between the aqueous milk components and compartmentalized fat. This interface allows controlled release of the lipolysis products and transfer of polar materials into milk serum (aqueous phase). The bipolar characteristics of the membrane are also necessary for the emulsion stability of the globules themselves; thus, the structure of human milk provides readily available fatty acids and cholesterol for micellar absorption in the small intestine.

Proteins, carbohydrates, and designer fats for optimal brain development

Human milk provides appropriate amounts of proteins (primarily alpha-lactalbumin and whey), carbohydrates (lactose), minerals, vitamins, and fats for the growing term infant. The fats are composed of cholesterol, triglycerides, short-chain fatty acids, and long-chain polyunsaturated (LCP) fatty acids. The LCP fatty acids (18- to 22-carbon length) are needed for brain and retinal development. Large amounts of omega-6 and omega-3 LCP fatty acids, predominately the 20-carbon arachidonic acid (AA) and the 22-carbon docosahexaenoic acids (DHAs), are deposited in the developing brain and retina during prenatal and early postnatal growth.

An infant, particularly a preterm infant, may have a limited ability to synthesize optimal levels of AA and DHA from linoleic and linolenic acid. Therefore, these 2 fatty acids may be considered essential fatty acids. Many infant formulas in the United States have added AA, DHA, or both. The amount of AA and DHA in breast milk varies with the maternal diet.[1, 9] The unique blend of fatty acids in the breast milk has been linked to the development of innate and adaptive immune regulation.

Prior to routine fortification of formulas with DHA and AA, infants who received breast milk demonstrated better visual acuity at age 4 months than formula-fed infants, as well as slightly enhanced cognitive development. This has not been a universal finding, however, and some have continued to doubt the benefits of DHA and ARA.

However, in a study of children at age 5 years who were breastfed and whose mothers were given a modest DHA supplement until 4 months postpartum, there was a significant improvement in sustained attention when compared to children whose mothers were not given DHA.[10]

A study compared growth and bone mineralization in very low birth weight infants fed preterm formula with those who received term formula; the conclusion was that preterm formula better aided in growth and development.[11]

One study examined maternal dietary manipulation of fatty acid concentration and neurodevelopmental differences in human milk.[12] Despite higher levels of AA and DHA in the heavily supplemented maternal groups, no differences were observed in the neurodevelopmental outcomes of the 3 groups. This finding supports a more global effect of human milk as opposed to a single agent that renders developmental differences.

Thus, whether healthy term infants benefit from the addition of DHA and AA to formula remains unclear because they are able to convert very LCP fatty acids to DHA and AA. Ill term infants and those born prematurely are most likely to benefit from formulas enriched with DHA, AA, or both.

Rather than producing better vision or greater intelligence, breast milk may somehow protect the developing neonatal brain from injury or less optimal development by providing necessary building materials and growth factors that act synergistically rather than in isolation.

A study by Dallas et al indicated that milk produced by women who deliver preterm demonstrates a high level of protein breakdown by endogenous proteases, with the investigators suggesting that such breakdown may reduce difficulties associated with the immature digestive systems of preterm infants. The study, which looked at a total of 32 term and 28 preterm milk samples (from eight mothers and 14 mothers, respectively), found preterm milk to have a significantly higher peptide count than term milk. Cleavage-site analysis suggested that the protease plasmin is more active in preterm milk and that cytosol aminopeptidase and carboxypeptidase B2 also break down milk proteins.[13]

Immunologic properties of human milk

Through the years, knowledge about the immune properties and effects of human milk has grown. A recommended comprehensive review by one of the pioneers in the field, Dr. Armand Goldman, appeared in Breastfeeding Medicine (2007).[14] Below are the highlights of just some of many known immune properties and functions of human milk.

  • Human milk immunoglobulins
    • Human milk contains all of the different antibodies (M, A, D, G, E), but secretory immunoglobulin A (sIgA) is the most abundant. Milk-derived sIgA is a significant source of passively acquired immunity for the infant during the weeks before the endogenous production of sIgA occurs. During this time of reduced neonatal gut immune function, the infant has limited defense against ingested pathogens. Therefore, sIgA is an important protective factor against infection.
    • Assuming that the mother and her infant, who are closely associated, share common flora, the antigenic specificity of the mother's sIgA in her milk is directed against the same antigens in the neonate. Maternal immunoglobulin A (IgA) antibodies derived from the gut and respiratory immune surveillance systems are transported via blood and lymphatic circulations to the mammary gland, ultimately to be extruded into her milk as sIgA. The packaging of IgA with a secretory component unique to the mammary gland protects the sIgA from stomach acids, allowing it to reach the small intestine intact.
  • Other immunologic properties of human milk
    • In addition to antibodies, human milk has numerous factors that can affect the intestinal microflora of the baby. These factors enhance the colonization of some bacteria while inhibiting the colonization by others. The immunologic components include lactoferrin, which binds to iron, thus making it unavailable to pathogenic bacteria; lysozyme, which enhances sIgA bactericidal activity against gram-negative organisms; oligosaccharides, which intercept bacteria and form harmless compounds that the baby excretes; milk lipids, which damage membranes of enveloped viruses; and mucins, which are present on the milk-fat globule membrane. Mucins adhere to bacteria and viruses and help eliminate them from the body. Interferon and fibronectin have antiviral activities and enhance lytic properties of milk leukocytes.
    • Our understanding of the interactional effect of these bioactive constituents, the impact of microbiota on gut function, and development (and role of human milk in that development) is just beginning to be understood.[15, 16] These constituents clearly have profound effects of the health status of individuals throughout life, particularly during infancy.
  • Human milk leukocytes
    • Macrophages comprise 40-60% of the cells in colostrum, with the remainder of cells primarily consisting of lymphocytes and polymorphonucleocytes. Extruded into the milk are rare mammary epithelial cells and the plasma membrane-bound lipid droplets referred to as milk-fat globules. By 7-10 days postpartum, with the transition from colostrum to mature milk, the percentage of macrophages then increases to 80-90% at a concentration of 104 -105 human milk macrophages per milliliter of milk. Milk leukocytes can tolerate extremes in pH, temperature, and osmolality. They have been shown to survive for as long as a week in baboons and lambs.
  • Passive immunity from mother to recipient breastfeeding infant
    • While awaiting endogenous maturation of the baby's own immunologic systems, various immunologic and bioactive milk components act synergistically to provide a passive immunologic support system from the mother to her infant in the first days to months after birth. Ingested milk passively immunizes the neonate. Numerous studies have clearly documented this scenario and its clinical benefit, demonstrating decreased risk for gastrointestinal and respiratory infections, particularly during the first year of life.
    • Evidence is increasing that these immune and bioactive substances prime the neonatal GI and immune systems in their selective recognition of antigens and development of cellular signaling. This may explain the decreased risk of intestinal and respiratory allergy in children who have been breastfed and the lower-than-predicted risk of autoimmune diseases in the breastfed population. Direct effects are difficult to prove given the multifactorial nature of such diseases; however, when taken together, the data support the beneficial nature of human milk for the developing infant.

Bioactive properties of human milk

Human milk also contains growth modulators, such as epidermal growth factor (EGF), nerve growth factor (NGF), insulinlike growth factors (IGFs), and interleukins. Transforming growth factor (TGF)–alpha, TGF-beta, and granulocyte colony-stimulating factor (G-CSF) are also identified in human milk. These growth modulators are produced either by the epithelial cells of the mammary gland or by activated macrophages, lymphocytes (mainly T cells), or neutrophils in the milk. EGF and TGF-alpha were found at higher concentrations in the milk of mothers who delivered prematurely compared with those who delivered at term. EGF, TGF-alpha, and human milk stimulate fetal small intestinal cell proliferation in vitro, with the greatest increase in cell proliferation seen following exposure to human milk.

Certain bioactive substances and live cells in milk appear to influence neonatal gut maturation and growth through their transfer of developmental information to the newborn. Although most of these biosubstances have been identified in mother's milk in quantities that exceed maternal serum levels, their exact role in human newborns is uncertain; most current information is from animal models whose development may significantly differ.

Conclusion

Human milk, in addition to its numerous nutrients that make it an ideal food source for the growing term infant, is a bioactive fluid that evolves from colostrum to mature milk as the infant matures. This bioactive fluid contains numerous factors and live cells that, in concert, promote the growth and well-being of the breastfeeding infant. Oliver Wendell Holmes said it best when he stated, "A pair of substantial mammary glands has the advantage over the two hemispheres of the most learned professor's brain, in the art of compounding a nutritious fluid for infants." With the ever-expanding knowledge resulting from current research, commercial formula clearly cannot replicate all of the valuable properties that are inherent in human milk.

For excellent patient education resources, visit eMedicineHealth's Pregnancy Center. Also, see eMedicineHealth's patient education article Breastfeeding.

Previous
 
Contributor Information and Disclosures
Author

Carol L Wagner, MD Professor of Pediatrics, Medical University of South Carolina

Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Womens Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Nutrition, Massachusetts Medical Society, National Perinatal Association, Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Brian S Carter, MD, FAAP Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Attending Physician, Division of Neonatology, Children's Mercy Hospital and Clinics; Faculty, Children's Mercy Bioethics Center

Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Pediatric Society, American Society for Bioethics and Humanities, American Society of Law, Medicine & Ethics, Society for Pediatric Research, National Hospice and Palliative Care Organization

Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Eastern Society for Pediatric Research, American Medical Association, Connecticut State Medical Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Acknowledgements

George Cassady, MD Clinical Professor, Department of Pediatrics, Stanford University School of Medicine

George Cassady, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Society for Pediatric Research, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

References
  1. Lawrence R, Lawrence RM. Breastfeeding. A Guide for the Medical Profession. 5th ed. St. Louis, MO: Mosby-Year Book, Inc; 2005.

  2. AAP,. ACOG. Breastfeeding Handbook for Physicians. 2006.

  3. Gartner LM, Morton J, Lawrence RA, et al. Breastfeeding and the use of human milk. Pediatrics. 2005 Feb. 115(2):496-506. [Medline].

  4. Hassiotou F, Geddes D. Anatomy of the human mammary gland: Current status of knowledge. Clin Anat. 2012 Sep 19. [Medline].

  5. Ramsay DT, Kent JC, Hartmann RA, Hartmann PE. Anatomy of the lactating human breast redefined with ultrasound imaging. J Anat. 2005 Jun. 206(6):525-34. [Medline].

  6. Haslam SZ, Shyamala G. Effect of oestradiol on progesterone receptors in normal mammary glands and its relationship with lactation. Biochem J. 1979 Jul 15. 182(1):127-31. [Medline].

  7. Haslam SZ, Shyamala G. Progesterone receptors in normal mammary glands of mice: characterization and relationship to development. Endocrinology. 1979 Sep. 105(3):786-95. [Medline].

  8. Riordan J, Auerbach KG. Breastfeeding and human lactation. Boston. Mass: Jones and Bartlett Publishers; 1993.

  9. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006 Jun. 83(6 Suppl):1467S-1476S. [Medline].

  10. Jensen CL, Voigt RG, Llorente AM, Peters SU, Prager TC, Zou YL. Effects of early maternal docosahexaenoic acid intake on neuropsychological status and visual acuity at five years of age of breast-fed term infants. J Pediatr. 2010 Dec. 157(6):900-5. [Medline].

  11. Chanda B, Venugopal SC, Kulshrestha S, et al. Glycerol-3-phosphate levels are associated with basal resistance to the hemibiotrophic fungus Colletotrichum higginsianum in Arabidopsis. Plant Physiol. 2008 Aug. 147(4):2017-29. [Medline]. [Full Text].

  12. Crawford MA. The role of essential fatty acids in neural development: implications for perinatal nutrition. Am J Clin Nutr. 1993 May. 57(5 Suppl):703S-709S; discussion 709S-710S. [Medline].

  13. Dallas DC, Smink CJ, Robinson RC, et al. Endogenous Human Milk Peptide Release Is Greater after Preterm Birth than Term Birth. J Nutr. 2014 Dec 24. [Medline].

  14. Goldman AS. The immune system in human milk and the developing infant. Breastfeed Med. 2007 Dec. 2(4):195-204. [Medline].

  15. Mshvildadze M, Neu J, Mai V. Intestinal microbiota development in the premature neonate: establishment of a lasting commensal relationship?. Nutr Rev. 2008 Nov. 66(11):658-63. [Medline].

  16. Walker AW, Duncan SH, Harmsen HJ, Holtrop G, Welling GW, Flint HJ. The species composition of the human intestinal microbiota differs between particle-associated and liquid phase communities. Environ Microbiol. 2008 Dec. 10(12):3275-83. [Medline].

  17. Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia. 1998 Jan. 3(1):23-35. [Medline].

  18. Beaudry M, Dufour R, Marcoux S. Relation between infant feeding and infections during the first six months of life. J Pediatr. 1995 Feb. 126(2):191-7. [Medline].

  19. Bines JE, Walker WA. Growth factors and the development of neonatal host defense. Adv Exp Med Biol. 1991. 310:31-9. [Medline].

  20. Birch DG, Birch EE, Hoffman DR, Uauy RD. Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids. Invest Ophthalmol Vis Sci. 1992 Jul. 33(8):2365-76. [Medline].

  21. Birch E, Birch D, Hoffman D, Hale L, Everett M, Uauy R. Breast-feeding and optimal visual development. J Pediatr Ophthalmol Strabismus. 1993 Jan-Feb. 30(1):33-8. [Medline].

  22. Briggs, GG, Freeman, RK, Yaffe, SJ. Drugs in pregnancy and lactation. A Reference Guide to Fetal and Neonatal Risk. 7th ed. Lippincott Williams & Wilkins; 2005.

  23. Carlson SE, Werkman SH, Rhodes PG, Tolley EA. Visual-acuity development in healthy preterm infants: effect of marine-oil supplementation. Am J Clin Nutr. 1993 Jul. 58(1):35-42. [Medline].

  24. Crago SS, Prince SJ, Pretlow TG, McGhee JR, Mestecky J. Human colostral cells. I. Separation and characterization. Clin Exp Immunol. 1979 Dec. 38(3):585-97. [Medline].

  25. Crawford MA, Doyle W, Drury P, Lennon A, Costeloe K, Leighfield M. n-6 and n-3 fatty acids during early human development. J Intern Med Suppl. 1989. 731:159-69. [Medline].

  26. Decsi T, Thiel I, Koletzko B. Essential fatty acids in full term infants fed breast milk or formula. Arch Dis Child Fetal Neonatal Ed. 1995 Jan. 72(1):F23-8. [Medline]. [Full Text].

  27. Duncan B, Ey J, Holberg CJ, Wright AL, Martinez FD, Taussig LM. Exclusive breast-feeding for at least 4 months protects against otitis media. Pediatrics. 1993 May. 91(5):867-72. [Medline].

  28. Farquharson J, Jamieson EC, Abbasi KA, Patrick WJ, Logan RW, Cockburn F. Effect of diet on the fatty acid composition of the major phospholipids of infant cerebral cortex. Arch Dis Child. 1995 Mar. 72(3):198-203. [Medline].

  29. Fendrick JL, Raafat AM, Haslam SZ. Mammary gland growth and development from the postnatal period to postmenopause: ovarian steroid receptor ontogeny and regulation in the mouse. J Mammary Gland Biol Neoplasia. 1998 Jan. 3(1):7-22. [Medline].

  30. Frawley LS, Porter TE. Milk factors as developmental regulators: the case for a mammotrope differentiating peptide. Endocrine. 1993. 1:241-6.

  31. Garofalo R, Chheda S, Mei F, et al. Interleukin-10 in human milk. Pediatr Res. 1995 Apr. 37(4 Pt 1):444-9. [Medline].

  32. Garofalo RP, Goldman AS. Expression of functional immunomodulatory and anti-inflammatory factors in human milk. Clin Perinatol. 1999 Jun. 26(2):361-77. [Medline].

  33. Goldman AS. The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr Infect Dis J. 1993 Aug. 12(8):664-71. [Medline].

  34. Goldman AS, Smith CW. Host resistance factors in human milk. J Pediatr. 1973 Jun. 82(6):1082-90. [Medline].

  35. Grosvenor CE, Picciano MF, Baumrucker CR. Hormones and growth factors in milk. Endocr Rev. 1993 Dec. 14(6):710-28. [Medline].

  36. Hamosh M. Enzymes in human milk. Jensen RG, ed. Handbook of Milk Composition. 1995. 388-427.

  37. Hamosh M, Peterson JA, Henderson TR, et al. Protective function of human milk: the milk fat globule. Semin Perinatol. 1999 Jun. 23(3):242-9. [Medline].

  38. Hanson LA, Ahlstedt S, Andersson B, et al. Protective factors in milk and the development of the immune system. Pediatrics. 1985 Jan. 75(1 Pt 2):172-6. [Medline].

  39. Hartmann PE. Changes in the composition and yield of the mammary secretion of cows during the initiation of lactation. J Endocrinol. 1973 Nov. 59(2):231-47. [Medline].

  40. Howie PW, Forsyth JS, Ogston SA, Clark A, Florey CD. Protective effect of breast feeding against infection. BMJ. 1990 Jan 6. 300(6716):11-6. [Medline].

  41. Isaacs CE, Thormar H. The role of milk-derived antimicrobial lipids as antiviral and antibacterial agents. Adv Exp Med Biol. 1991. 310:159-65. [Medline].

  42. Jensen RG, Blanc B, Patton S. Particulate constituents in human and bovine milks. Jensen RG, ed. Handbook of Milk Composition. San Diego, CA: Academic Press, Inc; 1995.

  43. Jensen RG, Ferris AM, Lammi-Keefe CJ. Human milk as a carrier of messages to the nursing infant. Nutrition Today. 1988. 6:20-5.

  44. Jensen RG, Ferris AM, Lammi-Keefe CJ. Lipids in human milk and infant formulas. Annu Rev Nutr. 1992. 12:417-41. [Medline].

  45. Keenan TW, Patton S. The structure of milk: Implications for sampling and storage. Jensen RG, ed. Handbook of Milk Composition. 1995. 5-50.

  46. Knishkowy B, Palti H, Adler B, Tepper D. Effect of otitis media on development: a community-based study. Early Hum Dev. 1991 Aug-Sep. 26(2):101-11. [Medline].

  47. Koldovsky O, Strbak V. Hormones and growth factors in human milk. Jensen RG, ed. Handbook of Milk Compostion. 1995. 428-36.

  48. Koletzko B. Fats for brains. Eur J Clin Nutr. 1992 Jun. 46 Suppl 1:S51-62. [Medline].

  49. Koletzko B, Braun M. Arachidonic acid and early human growth: is there a relation?. Ann Nutr Metab. 1991. 35(3):128-31. [Medline].

  50. Kuhn NF. Lactogenesis: The search for the trigger mechanism in different species. Peaker M, ed. Comparative Aspects of Lactation. 1977. 165.

  51. Kunz C, Rodriguez-Palmero M, Koletzko B, Jensen R. Nutritional and biochemical properties of human milk, Part I: General aspects, proteins, and carbohydrates. Clin Perinatol. 1999 Jun. 26(2):307-33. [Medline].

  52. Lucas A. Programming not metabolic imprinting. Am J Clin Nutr. 2000 Feb. 71(2):602. [Medline].

  53. Makrides M, Simmer K, Goggin M, Gibson RA. Erythrocyte docosahexaenoic acid correlates with the visual response of healthy, term infants. Pediatr Res. 1993 Apr. 33(4 Pt 1):425-7. [Medline].

  54. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr. 1992 Apr. 120(4 Pt 2):S129-38. [Medline].

  55. Morley R, Lucas A. Influence of early diet on outcome in preterm infants. Acta Paediatr Suppl. 1994 Dec. 405:123-6. [Medline].

  56. Neville MC. Volume and caloric density of human milk. Jensen RG, ed. Handbook of milk composition. 1995. 63.

  57. Neville MC. Physiology of lactation. Clin Perinatol. 1999 Jun. 26(2):251-79, v. [Medline].

  58. Paxson CL Jr, Cress CC. Survival of human milk leukocytes. J Pediatr. 1979 Jan. 94(1):61-4. [Medline].

  59. Peaker M, Neville MC. Hormones in milk: chemical signals to the offspring?. J Endocrinol. 1991 Oct. 131(1):1-3. [Medline].

  60. Pearlman WH. Hormones and tissue growth factors in milk: evolutionary implications. Endocr Regul. 1991 Jun. 25(1-2):4-9. [Medline].

  61. Pechoux C, Clezardin P, Dante R, et al. Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. Differentiation. 1994 Aug. 57(2):133-41. [Medline].

  62. Ramsay DT, Kent JC, Owens RA, Hartmann PE. Ultrasound imaging of milk ejection in the breast of lactating women. Pediatrics. 2004 Feb. 113(2):361-7. [Medline].

  63. Rivas RA, el-Mohandes AA, Katona IM. Mononuclear phagocytic cells in human milk: HLA-DR and Fc gamma R ligand expression. Biol Neonate. 1994. 66(4):195-204. [Medline].

  64. Rodriguez-Palmero M, Koletzko B, Kunz C, Jensen R. Nutritional and biochemical properties of human milk: II. Lipids, micronutrients, and bioactive factors. Clin Perinatol. 1999 Jun. 26(2):335-59. [Medline].

  65. Rubin DH, Leventhal JM, Krasilnikoff PA, et al. Relationship between infant feeding and infectious illness: a prospective study of infants during the first year of life. Pediatrics. 1990 Apr. 85(4):464-71. [Medline].

  66. Ruuska T. Occurrence of acute diarrhea in atopic and nonatopic infants: the role of prolonged breast-feeding. J Pediatr Gastroenterol Nutr. 1992 Jan. 14(1):27-33. [Medline].

  67. Ruuska T, Vesikari T. A prospective study of acute diarrhoea in Finnish children from birth to 2 1/2 years of age. Acta Paediatr Scand. 1991 May. 80(5):500-7. [Medline].

  68. Sarett HP, Bain KR, O'Leary JC. Decisions on breast-feeding or formula feeding and trends in infant-feeding practices. Am J Dis Child. 1983 Aug. 137(8):719-25. [Medline].

  69. Schnorr KL, Pearson LD. Intestinal absorption of maternal leucocytes by newborn lambs. J Reprod Immunol. 1984 Aug. 6(5):329-37. [Medline].

  70. Semenov DV, Kanyshkova TG, Karotaeva NA, et al. Catalytic nucleotide-hydrolyzing antibodies in milk and serum of clinically healthy human mothers. Med Sci Monit. 2004 Feb. 10(2):BR23-33. [Medline].

  71. Smith CW, Goldman AS. The cells of human colostrum. I. In vitro studies of morphology and functions. Pediatr Res. 1968 Mar. 2(2):103-9. [Medline].

  72. Wagner CL. Human milk as a nutritional and bioactive substance. Queen JT, ed. Management of High-Risk Pregnancy. 4th ed. 1999. 537-41.

  73. Wagner CL, Anderson DM, Pittard WB 3rd. Special properties of human milk. Clin Pediatr (Phila). 1996 Jun. 35(6):283-93. [Medline].

  74. Wagner CL, Forsythe DW, Pittard WB. Variation in the biochemical forms of transforming growth factor-alpha present in human milk and secreted by human milk macrophages. Biol Neonate. 1995. 68(5):325-33. [Medline].

  75. Wagner CL, Wagner MT. The breast or the bottle? Determinants of infant feeding behaviors. Clin Perinatol. 1999 Jun. 26(2):505-25. [Medline].

  76. Walker WA. Pathophysiology of intestinal uptake and absorption of antigens in food allergy. Ann Allergy. 1987 Nov. 59(5 Pt 2):7-16. [Medline].

  77. Wilde CJ, Addey CV, Boddy LM, Peaker M. Autocrine regulation of milk secretion by a protein in milk. Biochem J. 1995 Jan 1. 305 (Pt 1):51-8. [Medline].

  78. Wirt DP, Adkins LT, Palkowetz KH, Schmalstieg FC, Goldman AS. Activated and memory T lymphocytes in human milk. Cytometry. 1992. 13(3):282-90. [Medline].

  79. Yolken RH, Peterson JA, Vonderfecht SL, Fouts ET, Midthun K, Newburg DS. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. J Clin Invest. 1992 Nov. 90(5):1984-91. [Medline]. [Full Text].

 
Previous
Next
 
Schematic diagram of the breast.
Frontal view of lactating breast.
Myoepithelial cells, open and contracting.
The pathways for milk secretion and synthesis by the mammary epithelial cell. I: Exocytosis of milk protein, lactose, and other components of the aqueous phase in Golgi-derived secretory vesicles. II: Milk fat secretion via the milk fat globule. III: Direct movement of monovalent ions, water, and glucose across the apical membrane of the cell. IV: Transcytosis of components of the interstitial space. V: The paracellular pathway for plasma components and leukocytes. Pathway V is open only during pregnancy, involution, and in inflammatory states such as mastitis. SV = Secretory vesicle; RER = Rough endoplasmic reticulum; BM = Basement membrane; MFG = Milk fat globule; CLD = Cytoplasmic lipid droplet; N = Nucleus; PC = Plasma cell; FDA = Fat-depleted adipocyte; TJ = Tight junction; GJ = Gap junction; D = Desmosome; ME = Myoepithelial cell.
Lactose, protein, and total lipid concentrations in human milk.
(A) Ultrasound image of milk duct in the lactating breast. The duct appears as a branching hypoechoic structure within echogenic glandular tissue. (B) The ducts focused on the nipple (N) to the periphery of the breast. The walls are echogenic (up arrow) and the lumen hypoechoic (asterisk). The first branch of this duct (-->) is imaged almost directly under the nipple.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.